Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metatropic dwarfism × Cetuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 278 Squamous Cell Carcinoma of Head and Neck 147 Head and Neck Neoplasms 129 Carcinoma, Non-Small-Cell Lung 84 Colonic Neoplasms 79 Rectal Neoplasms 72 Neoplasm Metastasis 62 Neoplasms 51 Pancreatic Neoplasms 36 Carcinoma, Squamous Cell 34 Lung Neoplasms 31 Esophageal Neoplasms 24 Breast Neoplasms 20 Stomach Neoplasms 19 Recurrence 19 Laryngeal Neoplasms 16 Carcinoma 16 Mouth Neoplasms 15 Esophageal Squamous Cell Carcinoma 14 Tongue Neoplasms 12 Oropharyngeal Neoplasms 12 Adenocarcinoma Of Esophagus 12 Colorectal Cancer Metastatic 11 Hypopharyngeal Neoplasms 10 Adenocarcinoma of Lung 10 Salivary Gland Neoplasms 9 Parkinson Disease 4, Autosomal Dominant Lewy Body 9 Ovarian Neoplasms 9 Neoplasms, Squamous Cell 9 Uterine Cervical Neoplasms 8

Interventions

Vinorelbine 1 Genz-644282 1 Gemcitabine 1 Everolimus 1 Drug Therapy 1 Cisplatin 1 Cilengitide 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed

232 enrolled 17 charts

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡